282 related articles for article (PubMed ID: 25093849)
1. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials.
Li Q; Yan H; Liu W; Zhen H; Yang Y; Cao B
PLoS One; 2014; 9(8):e104346. PubMed ID: 25093849
[TBL] [Abstract][Full Text] [Related]
2. Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer.
Li Q; Yuan Z; Yan H; Wen Z; Zhang R; Cao B
Clin Ther; 2014 Jul; 36(7):1054-63. PubMed ID: 24986485
[TBL] [Abstract][Full Text] [Related]
3. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Cunningham D; Chau I; Stocken DD; Valle JW; Smith D; Steward W; Harper PG; Dunn J; Tudur-Smith C; West J; Falk S; Crellin A; Adab F; Thompson J; Leonard P; Ostrowski J; Eatock M; Scheithauer W; Herrmann R; Neoptolemos JP
J Clin Oncol; 2009 Nov; 27(33):5513-8. PubMed ID: 19858379
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
Jin SF; Fan ZK; Pan L; Jin LM
Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
[TBL] [Abstract][Full Text] [Related]
6. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.
Heinemann V; Boeck S; Hinke A; Labianca R; Louvet C
BMC Cancer; 2008 Mar; 8():82. PubMed ID: 18373843
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone.
Xie de R; Liang HL; Wang Y; Guo SS
Chin J Dig Dis; 2006; 7(1):49-54. PubMed ID: 16412038
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis.
Ouyang G; Liu Z; Huang S; Li Q; Xiong L; Miao X; Wen Y
World J Surg Oncol; 2016 Feb; 14():59. PubMed ID: 26927942
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
Herrmann R; Bodoky G; Ruhstaller T; Glimelius B; Bajetta E; Schüller J; Saletti P; Bauer J; Figer A; Pestalozzi B; Köhne CH; Mingrone W; Stemmer SM; Tàmas K; Kornek GV; Koeberle D; Cina S; Bernhard J; Dietrich D; Scheithauer W; ;
J Clin Oncol; 2007 Jun; 25(16):2212-7. PubMed ID: 17538165
[TBL] [Abstract][Full Text] [Related]
14. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials.
Ciliberto D; Botta C; Correale P; Rossi M; Caraglia M; Tassone P; Tagliaferri P
Eur J Cancer; 2013 Feb; 49(3):593-603. PubMed ID: 22989511
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
Schultheis B; Reuter D; Ebert MP; Siveke J; Kerkhoff A; Berdel WE; Hofheinz R; Behringer DM; Schmidt WE; Goker E; De Dosso S; Kneba M; Yalcin S; Overkamp F; Schlegel F; Dommach M; Rohrberg R; Steinmetz T; Bulitta M; Strumberg D
Ann Oncol; 2017 Oct; 28(10):2429-2435. PubMed ID: 28961832
[TBL] [Abstract][Full Text] [Related]
16. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
Yanagimoto H; Ishii H; Nakai Y; Ozaka M; Ikari T; Koike K; Ueno H; Ioka T; Satoi S; Sho M; Okusaka T; Tanaka M; Shimokawa T; Kwon AH; Isayama H
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):761-6. PubMed ID: 24925464
[TBL] [Abstract][Full Text] [Related]
17. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
Liu Y; Huang QK; Hong WD; Wu JM; Sun XC
Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):254-60. PubMed ID: 25304193
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
[TBL] [Abstract][Full Text] [Related]
20. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.
Barone C; Cassano A; Corsi DC; Pozzo C; Longo R; Schinzari G; Quirino M; Battelli C; Basso M
Oncology; 2003; 64(2):139-45. PubMed ID: 12566911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
